{"slug":"endometrial","tag":"endometrial","variants":["endometrial"],"description":"No description yet","count":9,"kinds":{"person":9},"related":[{"slug":"trialist","tag":"trialist","shared":6},{"slug":"gynaecological","tag":"gynaecological","shared":4},{"slug":"immunotherapy","tag":"immunotherapy","shared":3},{"slug":"radiotherapy","tag":"radiotherapy","shared":2},{"slug":"genomics","tag":"genomics","shared":1},{"slug":"molecular-classification","tag":"molecular-classification","shared":1},{"slug":"nrg-oncology","tag":"nrg-oncology","shared":1},{"slug":"ovarian","tag":"ovarian","shared":1},{"slug":"surgery","tag":"surgery","shared":1}],"records":[{"id":"mansoor-raza-mirza","kind":"person","name":"Mansoor Raza Mirza","route":"/people/mansoor-raza-mirza/","tldr":"Led NOVA and RUBY, the trials that established niraparib maintenance in ovarian cancer and dostarlimab in advanced endometrial cancer."},{"id":"ramez-eskander","kind":"person","name":"Ramez N. Eskander","route":"/people/ramez-eskander/","tldr":"Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease."},{"id":"carien-creutzberg","kind":"person","name":"Carien L. Creutzberg","route":"/people/carien-creutzberg/","tldr":"Led the PORTEC trials that defined who needs radiotherapy for endometrial cancer and brought molecular classification into treatment decisions."},{"id":"douglas-levine","kind":"person","name":"Douglas A. Levine","route":"/people/douglas-levine/","tldr":"Surgeon-scientist who led the TCGA endometrial cancer study that created today's four molecular subtypes."},{"id":"vicky-makker","kind":"person","name":"Vicky Makker","route":"/people/vicky-makker/","tldr":"New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy."},{"id":"shannon-westin","kind":"person","name":"Shannon N. Westin","route":"/people/shannon-westin/","tldr":"Houston gynaecologic oncologist who led DUO-E, the trial that added durvalumab, with or without olaparib, to first-line chemotherapy for advanced endometrial cancer."},{"id":"remi-nout","kind":"person","name":"Remi A. Nout","route":"/people/remi-nout/","tldr":"Dutch radiation oncologist who was lead author of PORTEC-2, the trial that showed vaginal brachytherapy is as good as pelvic radiotherapy for high-intermediate-risk endometrial cancer, with fewer side effects."},{"id":"ana-oaknin","kind":"person","name":"Ana Oaknin","route":"/people/ana-oaknin/","tldr":"Barcelona oncologist who led GARNET, the trial that brought dostarlimab to mismatch repair-deficient endometrial cancer, and who has led many trials of new drugs for gynaecological cancers."},{"id":"amanda-fader","kind":"person","name":"Amanda Nickles Fader","route":"/people/amanda-fader/","tldr":"Baltimore gynaecologic oncologist who led the trial showing that adding trastuzumab to chemotherapy helps women with HER2-positive uterine serous carcinoma, an aggressive form of endometrial cancer."}]}